Delayed
Nasdaq Helsinki
07:56:29 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
2
EUR
|
-0.50%
|
|
-3.38%
|
+26.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
471.5
|
477.3
|
250.8
|
124.3
|
171.7
|
-
|
-
|
Enterprise Value (EV)
1 |
417.4
|
401.5
|
189
|
124.3
|
140.7
|
150.4
|
156.7
|
P/E ratio
|
-20.2
x
|
-22.7
x
|
-11
x
|
-6.1
x
|
-10.3
x
|
-14.4
x
|
-26.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
686
x
|
239
x
|
71.9
x
|
48.4
x
|
22.9
x
|
11.8
x
|
6.67
x
|
EV / Revenue
|
608
x
|
201
x
|
54.2
x
|
48.4
x
|
18.8
x
|
10.3
x
|
6.09
x
|
EV / EBITDA
|
-22.9
x
|
-22.7
x
|
-9.93
x
|
-6.34
x
|
-10.8
x
|
-19.3
x
|
-71.1
x
|
EV / FCF
|
-25.3
x
|
-18.2
x
|
-6.47
x
|
-
|
44.7
x
|
-16.2
x
|
-26.4
x
|
FCF Yield
|
-3.95%
|
-5.5%
|
-15.5%
|
-
|
2.24%
|
-6.16%
|
-3.78%
|
Price to Book
|
7.53
x
|
5.65
x
|
2.88
x
|
-
|
3.19
x
|
3.72
x
|
3.65
x
|
Nbr of stocks (in thousands)
|
66,600
|
72,535
|
78,364
|
78,434
|
85,445
|
-
|
-
|
Reference price
2 |
7.080
|
6.580
|
3.200
|
1.585
|
2.010
|
2.010
|
2.010
|
Announcement Date
|
21-02-26
|
22-02-22
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.687
|
2
|
3.487
|
2.566
|
7.485
|
14.6
|
25.75
|
EBITDA
1 |
-18.2
|
-17.7
|
-19.03
|
-19.6
|
-13.06
|
-7.795
|
-2.205
|
EBIT
1 |
-19.42
|
-19.7
|
-21.41
|
-22.48
|
-16.36
|
-11.38
|
-6.255
|
Operating Margin
|
-2,827.22%
|
-985%
|
-613.97%
|
-875.92%
|
-218.57%
|
-77.95%
|
-24.29%
|
Earnings before Tax (EBT)
1 |
-19.44
|
-19.69
|
-22.06
|
-20.73
|
-15.29
|
-11.28
|
-6.205
|
Net income
1 |
-19.44
|
-19.7
|
-22.08
|
-20.76
|
-15.3
|
-11.28
|
-6.29
|
Net margin
|
-2,829.84%
|
-985%
|
-633.07%
|
-808.89%
|
-204.48%
|
-77.26%
|
-24.43%
|
EPS
2 |
-0.3500
|
-0.2900
|
-0.2900
|
-0.2600
|
-0.1950
|
-0.1400
|
-0.0750
|
Free Cash Flow
1 |
-16.49
|
-22.09
|
-29.21
|
-
|
3.15
|
-9.265
|
-5.93
|
FCF margin
|
-2,400.63%
|
-1,104.28%
|
-837.54%
|
-
|
42.08%
|
-63.46%
|
-23.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-02-26
|
22-02-22
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.475
|
0.66
|
0.76
|
0.89
|
0.85
|
0.986
|
0.744
|
0.78
|
0.641
|
0.401
|
0.94
|
1.18
|
1.09
|
5.95
|
EBITDA
1 |
-4.615
|
-4.8
|
-4.6
|
-5.484
|
-4.19
|
-4.784
|
-4.493
|
-5.372
|
-4.38
|
-5.353
|
-4.38
|
-4.06
|
-3.67
|
-0.31
|
EBIT
1 |
-5.108
|
-5.4
|
-
|
-6.07
|
-4.8
|
-5.43
|
-5.148
|
-6.103
|
-5.102
|
-6.122
|
-5.13
|
-4.9
|
-4.5
|
-1.2
|
Operating Margin
|
-1,075.37%
|
-818.18%
|
-
|
-682.02%
|
-564.71%
|
-550.71%
|
-691.94%
|
-782.44%
|
-795.94%
|
-1,526.68%
|
-545.74%
|
-415.25%
|
-412.84%
|
-20.17%
|
Earnings before Tax (EBT)
1 |
-4.512
|
-5.566
|
-
|
-6.055
|
-5.151
|
-5.57
|
-
|
-
|
-4.116
|
-5.331
|
-4.5
|
-5.6
|
-3.5
|
-0.4
|
Net income
1 |
-4.513
|
-5.6
|
-5.3
|
-6.058
|
-5.16
|
-5.568
|
-4.491
|
-6.804
|
-4.122
|
-5.339
|
-5.13
|
-4.9
|
-4.5
|
0.52
|
Net margin
|
-950.11%
|
-848.48%
|
-697.37%
|
-680.67%
|
-607.06%
|
-564.71%
|
-603.63%
|
-872.31%
|
-643.06%
|
-1,331.42%
|
-545.74%
|
-415.25%
|
-412.84%
|
8.74%
|
EPS
|
-0.0600
|
-0.0800
|
-0.0700
|
-0.0800
|
-0.0700
|
-0.0700
|
-0.0600
|
-0.0900
|
-0.0500
|
-0.0700
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-25
|
22-02-22
|
22-05-24
|
22-08-25
|
22-11-29
|
23-02-28
|
23-05-25
|
23-08-24
|
23-11-22
|
24-02-29
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
54.2
|
75.7
|
61.8
|
-
|
31
|
21.3
|
15
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.5
|
-22.1
|
-29.2
|
-
|
3.15
|
-9.27
|
-5.93
|
ROE (net income / shareholders' equity)
|
-55.1%
|
-26.8%
|
-25.7%
|
-
|
-23.4%
|
-14.7%
|
1.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.9400
|
1.160
|
1.110
|
-
|
0.6300
|
0.5400
|
0.5500
|
Cash Flow per Share
2 |
-0.2500
|
-0.2100
|
-0.2600
|
-
|
0.3000
|
-
|
-
|
Capex
1 |
2.34
|
7.74
|
9.13
|
-
|
2.65
|
3.1
|
4.25
|
Capex / Sales
|
340.06%
|
386.84%
|
261.7%
|
-
|
35.4%
|
21.23%
|
16.5%
|
Announcement Date
|
21-02-26
|
22-02-22
|
23-02-28
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
2.01
EUR Average target price
4.4
EUR Spread / Average Target +118.91% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.18% | 185M | | +23.37% | 47.02B | | +50.01% | 41.86B | | -0.94% | 41.76B | | -4.32% | 28.8B | | +11.29% | 26.05B | | -20.92% | 19.15B | | +3.20% | 12.55B | | -2.67% | 11.82B | | +30.23% | 12.34B |
Other Biotechnology & Medical Research
|